3Nichools SJ ,Tuzcu EM ,Sipahi I,et al. Effects of obesity onlipid - lowering, anti - inflammatory, and antiatheroselerotic benefits of atorvastatin or pravastat - in patients with coronary artery disease [ J ]. Am J Cardiol, 2006,97 ( 11 ) : 1553.
4Frobert O, Hollnager P, Jensen KM, et al. Effect of acutechanges in oxygen tension on flow - mediated dilation. Relation to eardivaseular risk [ J ]. Seand Cardiovasc ,2008,42 ( 1 ) :38.
5Maat MP, Kluft C. Determinants of C - reactiove proteinconcentration in blood [ J ]. Ltal Heart J,2001,2 (3) : 189.
6Dionede L,Albani D,Sottoeorno M,et al. In vivo anti -in-flammatory effect of statins is mediated by nonsterol mevalonate products [ J ]. Arterioscler Thromb Vasc Biol,2001,21 ( 8 ) : 1327.
7Stefanadis C, Toutouzas K, Tsiamis E, et al. Relation be-tween local temperature and C -reactive protein levels in patients with coronary artery disease : effects of atorvastatin treatment [ J]. Atherosclerosis ,2007,192 (2) :396.
8Miyauehi K, Kimura T, Morimoto T, et al. Japan assessmentof pitavastatin and atorvastatin in acute coronary syndrome. (JA- PAN - ACS) : rationale and design [ J ] . Circ J, 2006,70 ( 12 ) : 1624.
9Wong B, Lumma WC, Smith AM, et al. Statins suppressTHP - 1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgernalation [ J ]. J Leukoc Biol, 2001,69 ( 6 ) : 959.
10Capurso A. Le promesse delle statine: The promise of st-atins[ J]. Ital Heart J,2001,2(2) :224.
2Grundy SM,Cleeman JI,Merz CN,et al.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines.Circulation,2004,110:227-239.
3Spencer FA,Allegrone J,Goldberg RJ,et al.Association of statin therapy with outcomes of acute coronary syndrome:The GRACE study.Ann Intern Med,2004,140:857-866.
4Cannon CP,I Braunwald E,McCabe C,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,2004,350:1495-1504.
5Naghavi M,Libby P,Falk E,et al.From vulnerable plaque to vulnerable patient:a call for new definitions and risk assessment strategies:Part Ⅰ.Circulation,2003,108:1664-1672.
7LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005,352:1425-1435.
8von Birgelen C,Hartmann M,Mintz GS,et al.Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (12 months) follow-up intravascular ultrasound.Circulation,2003,108:2757-2762.
9Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial.JAMA,2004,291:1071-1080.
10O'Keefe JH,Cordain L,Harris WH,et al.Optimal low-density lipoprotein is 50 to 70 mg/dl.Lower is better and physiologically normal.J Am Coll Cardiol,2004,43:2142-2146.
8Schmitz G,Langmann T. Pharmacogenomics of cholester- ol-lowering therapy[J]. Vascul Pharmacol, 2006,44 (2) : 75-89.
9Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E,apo- lipoprotein B,and cholesterol metabolism[J]. Am J Hum Genet. 1988,42(1) :104-112.
10Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury[J]. Circulation, 2006, 114(16):597-605.
